Area of research
Hematology · Genetics
Research interest
Research interests include Hemoglobinopathies and Related Disorders, Hematopoietic Stem Cell Transplantation, Iron Metabolism and Disorders, and Acute Myeloid Leukemia Research.
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease
Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial
UCL Discovery (University College London) 2022cited by 74position: middle
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the <scp>SPIN</scp> trial
Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium
Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low‐resource setting: evidence from the SPRING trial
Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial
End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative
Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis
Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study
Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma
Multiple Myeloma, Version 2.2016
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation
Salvage Second Hematopoietic Cell Transplantation in Myeloma
Multiple Myeloma, Version 1.2013
Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013